What is HC Wainwright’s Forecast for RNAC Q1 Earnings?

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) – Analysts at HC Wainwright issued their Q1 2026 EPS estimates for Cartesian Therapeutics in a note issued to investors on Monday, May 19th. HC Wainwright analyst M. Kapoor anticipates that the company will post earnings per share of ($0.80) for the quarter. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Cartesian Therapeutics’ current full-year earnings is $4.56 per share. HC Wainwright also issued estimates for Cartesian Therapeutics’ Q2 2026 earnings at ($0.94) EPS, Q3 2026 earnings at ($1.10) EPS, Q4 2026 earnings at ($1.22) EPS and FY2026 earnings at ($4.06) EPS.

Cartesian Therapeutics (NASDAQ:RNAC) last released its earnings results on Thursday, May 8th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.07). The firm had revenue of $1.10 million for the quarter, compared to analyst estimates of $0.69 million.

Separately, Needham & Company LLC decreased their target price on shares of Cartesian Therapeutics from $41.00 to $40.00 and set a “buy” rating for the company in a research report on Thursday, May 8th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $42.50.

Cartesian Therapeutics Price Performance

Shares of RNAC stock opened at $10.37 on Tuesday. Cartesian Therapeutics has a fifty-two week low of $8.85 and a fifty-two week high of $41.87. The stock’s 50-day moving average is $12.17 and its two-hundred day moving average is $16.57. The firm has a market cap of $269.14 million, a P/E ratio of -0.20 and a beta of 0.51.

Hedge Funds Weigh In On Cartesian Therapeutics

Several large investors have recently bought and sold shares of RNAC. Virtus ETF Advisers LLC acquired a new position in Cartesian Therapeutics during the 4th quarter valued at $63,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Cartesian Therapeutics by 22.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,562 shares of the company’s stock valued at $82,000 after purchasing an additional 847 shares during the last quarter. Wells Fargo & Company MN increased its holdings in Cartesian Therapeutics by 112.7% in the 4th quarter. Wells Fargo & Company MN now owns 4,847 shares of the company’s stock valued at $87,000 after buying an additional 2,568 shares during the period. Corebridge Financial Inc. lifted its holdings in shares of Cartesian Therapeutics by 32.6% during the 4th quarter. Corebridge Financial Inc. now owns 5,122 shares of the company’s stock worth $92,000 after acquiring an additional 1,258 shares during the period. Finally, AlphaQuest LLC bought a new stake in Cartesian Therapeutics in the first quarter valued at about $95,000. 86.95% of the stock is currently owned by institutional investors and hedge funds.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.